SynapCell to present at AEDD TRIALS XVI
June 16-18 2021
Lost in translation? Meet the GAERS!
Join top experts in epilepsy at this not-to miss epilepsy-focused (e-)gathering in Pennsylvania bringing together representatives from academia, industry, the NIH, and the FDA to review what has been learned and to discuss strategies to enhance AEDD development.
So proud to present our impact on improving AED development with our translational models. A special attention will be given to the GAERS, one of the best models of generalized absence epilepsy available, acclaimed by the scientific community and pharmaceutical companies such as Pfizer with whom we had the chance to publish amazing results with their compound on the GAERS.
Friday, June 18
SESSION VIII: DRUG PIPELINE-PRECLINICAL
Moderator: Marc Dichter, MD
Title: LOST IN TRANSLATION? Meet the GAERS
The GAERS: a translational model, exclusive to SynapCell.
Loop translation from preclinical to clinical applications with the predictive properties of the EEG biomarker SWD.
Drug discovery applications of the GAERS: from seizure monitoring to de-risking seizure-aggravation.
We look forward to discussing with you th!
Featured SPEAKER
Corinne ROUCARD, PhD
Chief Executive Officer
SynapCell
“I co-founded SynapCell in 2005 and became its CEO since then with the same enthusiasm as the very first day with the company. With over 15 years’ experience in epilepsy, SynapCell has been supporting drug discovery programs for its Pharmaceutical, academia and biotech customers in the long run, leading to the selection of several drug candidates for the clinical phases.
We are recognized as leaders in epilepsy by our pairs with returning customers that appreciate our flexibility and ability to push the boundaries of neuroscience to write the next pages of AED drug discovery roadmap. Our integration into the ambitious NINDS ETSP program, incorporating our well-mastered MTLE mouse model of Temporal Lobe Epilepsy (TLE) is a proof that our hard work in delivering high quality results and running the extra mile with relentless efforts has paid off.
It is our duty to assist the discovery of new treatments for patients, and I always keep in mind the need to develop innovative drug discovery solutions that are as translational as possible and inspired by a bedside to bench strategy.”
Can’t make it this time? So let’s have a call!